Power 3 Medical Products, specializing in the development and commercialization of early detection diagnostic tests for breast cancer and neurodegenerative diseases, announced a new international collaboration. Power3, in partnership with the Princess Haya Biotechnology Center and the Jordan University of Science and Technology will begin a clinical validation study for Power3's BC-SeraPro(TM) Breast Cancer diagnostic blood test. The collaborative project will significantly expand Power3's already-extensive breast cancer patient database and will further validate the pioneering work Power3 has already completed in the discovery of blood serum-based biomarkers of disease.

The Princess Haya Biotechnology Center and the Jordan University of Science and Technology will provide Power3 with clinically confirmed breast cancer, benign breast disease and age-matched control patient samples. Power3 will use its proprietary and patent-pending technologies to analyze these samples, in a further validation of the company's panel of protein biomarkers for the early detection of breast cancer.

Power3 has previously reported results of a 60 patient, blinded breast cancer detection validation study. Using one of the company's proprietary bio-analytical methods, this validation study produced results of 97% sensitivity and 93% specificity. In addition, using a more robust and flexible bio-analytical statistical model, Power3 achieved 80% sensitivity and 87% specificity in the blinded breast cancer detection study.

Once commercialized, BC-SeraPro(TM) will have an enormous impact on how breast cancer will be diagnosed, monitored, and managed. Steven B. Rash, chairman and CEO of Power3, said he is hopeful that this collaboration with the Princess Haya Biotechnology Center will prove a major milestone towards offering the medical community a test that is accurate, utilitarian and inexpensive in the Middle East and in other international markets. The company expects to complete the clinical validation study in the third quarter 2008, and introduce the BC-SeraPro(TM) commercially in the first quarter of 2009.